z-logo
open-access-imgOpen Access
Comparative Studies of Biosimilar Medicinal Products
Author(s) -
О. Б. Талибов
Publication year - 2019
Publication title -
vedomosti naučnogo centra èkspertizy sredstv medicinskogo primeneniâ
Language(s) - English
Resource type - Journals
eISSN - 2619-1172
pISSN - 1991-2919
DOI - 10.30895/1991-2919-2019-9-2-93-100
Subject(s) - biosimilar , bioequivalence , comparability , immunogenicity , pharmacology , computational biology , medicine , biochemical engineering , pharmacokinetics , microbiology and biotechnology , biology , mathematics , engineering , immunology , immune system , combinatorics
The article describes specific aspects of biosimilars research and development. The aim of the study was to analyse the ways to conduct comparative studies of biotechnological medicinal products and the main approaches to the assessment of the obtained data. The paper highlights that biotechnological products are associated with a much higher potential variability of chemical and pharmacological characteristics than small molecules. The author analyses the reasons of this phenomenon, describes mechanisms underlying the microheterogeneity of protein molecules, primarily post-translational modification. The latter has an impact on the pharmacokinetic parameters, pharmacodynamics and immunogenicity of complex protein molecules, which increases the variability of test results and makes it difficult to conduct bioequivalence studies. In addition to bioequivalence studies, biosimilars research should include comparative studies of pharmacodynamics, evaluation of therapeutic equivalence and immunogenicity. Assessment of the medicines comparability should be based on the analysis of all data provided, which requires a more flexible and sometimes individual approach on the part of regulatory authorities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here